Association between levels of serum and urinary B cell-activating factor and systemic lupus erythematosus disease activity

• Published in: Archives of rheumatology 2023-09, Vol.38 (3), p.429-440
• Main Authors: Rezazadeh, Maryam, Jokar, Mohammad Hasan, Aghili, Seyedeh Mehrnaz, Mirfeizi, Zahra, Mahmoudi, Mahmoud, Morovatdar, Negar, Hashemzadeh, Kamila
• Format: Article
• Language: English
• Subjects: B cells; Belimumab; Development and progression; Lupus; Medical research; Medicine, Experimental; Original; Systemic lupus erythematosus
• ISSN: 2148-5046; 2618-6500
• DOI: 10.46497/ArchRheumatol.2023.9549

Objectives: This study investigated the correlation between serum and urinary B cell-activating factor (BAFF) levels and systemic lupus erythematosus (SLE) disease activity. Patients and methods: This case-control study was conducted with 87 participants between December 2020 and September 2021. Sixty-two SLE patients who fulfilled the eligibility criteria were enrolled. SLE patients were categorized into active (n=34) and inactive (n=28) groups based on their Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores. The control group consisted of 25 healthy subjects. Serum and urine samples were collected for the measurement of BAFF levels. Finally, the relationship between these variables and SLE disease activity was investigated. Results: The mean age of active (SLEDAI-2K >4) and inactive (SLEDAI-2K [less than or equal to]4) SLE patients and healthy individuals were 32.8[+ or -]7.8, 32.5[+ or -]6.8, and 31.7[+ or -]7.8 years, respectively (p=0.62). The median serum BAFF (s-BAFF) and urinary BAFF (u-BAFF) in active lupus patients (10.4 [2.3] ng/mL and 8.2 [3.7] ng/mL, respectively) were significantly higher than in inactive lupus patients (6 (7.1) ng/mL and 1.7 (4.7) ng/mL, respectively; p